» Articles » PMID: 18958556

Diffuse Malignant Pleural Mesothelioma: a Multi-institutional Clinicopathological Study

Overview
Journal Surg Today
Specialty General Surgery
Date 2008 Oct 30
PMID 18958556
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The relative rarity of malignant pleural mesothelioma (MPM) in Japan makes it difficult to perform a large-scale clinicopathological study of this tumor at a single institute. Thus, we performed a multiinstitutional study to evaluate the current status of diagnosis and treatment in Japan.

Methods: We analyzed the records of 65 patients with MPM, obtained from the 13 institutions comprising the Japanese Chiba Multicenter Study Group.

Results: In 56 patients, the tumor was detected after a visit to a medical facility for subjective symptoms such as chest pain, shortness of breath, and cough. It took a median period of 2 months from the initial visit to establish the diagnosis. The overall survival rates of 33 patients with unresectable MPM 1, 2, and 3 years after the diagnosis were 40.5%, 10.8%, and 0%, respectively, whereas those of 32 patients who underwent surgery were 67.9%, 35.0% and 10.9%, respectively (P=0.0035). According to multivariate analysis, histological type, International Mesothelioma Interest Group clinical stage, sex, and the presenting symptom of shortness of breath were significant prognostic factors.

Conclusions: The definitive diagnosis of early MPM is difficult, but establishing the best diagnostic modality would improve survival rates, since radical surgery is likely to be effective for resectable disease.

Citing Articles

Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients.

Holzknecht A, Illini O, Hochmair M, Krenbek D, Setinek U, Huemer F Cancers (Basel). 2022; 14(9).

PMID: 35565374 PMC: 9104590. DOI: 10.3390/cancers14092245.


Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.

Taioli E, van Gerwen M, Mihalopoulos M, Moskowitz G, Liu B, Flores R J Thorac Dis. 2018; 9(12):5423-5433.

PMID: 29312753 PMC: 5756994. DOI: 10.21037/jtd.2017.11.55.

References
1.
Rusch V, Piantadosi S, Holmes E . The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg. 1991; 102(1):1-9. View

2.
Rusch V . A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995; 108(4):1122-8. DOI: 10.1378/chest.108.4.1122. View

3.
Allen K, Faber L, Warren W . Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy. Chest Surg Clin N Am. 1994; 4(1):113-26. View

4.
Kanazawa N, Ioka A, Tsukuma H, Ajiki W, Oshima A . Incidence and survival of mesothelioma in Osaka, Japan. Jpn J Clin Oncol. 2006; 36(4):254-7. DOI: 10.1093/jjco/hyl018. View

5.
Boersma A, Degand P, BISERTE G . Hyaluronic acid analysis and the diagnosis of pleural mesothelioma. Bull Eur Physiopathol Respir. 1980; 16(1):41-5. View